Startups
Oral antifungal therapy developer to treat life-threatening rare fungal infections
Summary
Investors
- Advent Life Sciences Series D
- Advent Life Sciences Series D
- Intermediate Capital Group Series D
- Intermediate Capital Group Series D
- Intermediate Capital Group Series D
- Novo Holdings A/S Series D
- Forbion Capital Partners Series D
- Forbion Capital Partners Series D
- Sofinnova Partners Series D
- Sofinnova Partners Series D
- Sofinnova Partners Series D
- Sofinnova Partners Series D
- Merifin Capital Series D
- Morningside Ventures Series D
- Blue Owl Series D
- AMR Action Fund Series D
- Novo A/S Unknown
- Novo A/S Unknown
- Sofinnova Partners Unknown
- Sofinnova Partners Unknown
- Sofinnova Partners Unknown
- Sofinnova Partners Unknown
- Forbion Capital Partners Unknown
- Forbion Capital Partners Unknown
Full Company Profile
- Access details of the company management, and other intelligence on this company by registering for Seedtable